Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARIISE - ASCs in recently diagnosed non-ischemic heart failure
2025-520837-22-00Phase 2Completed
- Sponsor
- Cell to Cure
- Start
- Dec 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing C2C_ASC110 with CryoStor CS10 placebo (2 arms). Primary endpoint: Change in left ventricular ejection fraction at 6 months. Started Dec 2025; status: completed.
02
Drugs
C2C_ASC110
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2025-520837-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520837-22-00.